iShares MSCI Turkey ETF (TUR) Reaches $43.61 Formed H&S; Cullen Capital Management Decreased Astrazeneca Plc (Adr) (AZN) Stake By $715,110

Cullen Capital Management Llc decreased Astrazeneca Plc (Adr) (AZN) stake by 1.21% reported in 2017Q3 SEC filing. Cullen Capital Management Llc sold 21,670 shares as Astrazeneca Plc (Adr) (AZN)’s stock rose 16.26%. The Cullen Capital Management Llc holds 1.76 million shares with $59.74 million value, down from 1.78 million last quarter. Astrazeneca Plc (Adr) now has $85.70 billion valuation. The stock decreased 0.53% or $0.19 during the last trading session, reaching $35.46. About 918,388 shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since January 16, 2017 and is uptrending. It has outperformed by 2.75% the S&P500.

iShares MSCI Turkey ETF (TUR) formed H&S with $40.99 target or 6.00% below today’s $43.61 share price. iShares MSCI Turkey ETF (TUR) has $349.03 million valuation. The ETF decreased 1.49% or $0.66 during the last trading session, reaching $43.61. About 54,275 shares traded. iShares MSCI Turkey ETF (NASDAQ:TUR) has risen 5.32% since January 16, 2017 and is uptrending. It has underperformed by 11.38% the S&P500.

Analysts await AstraZeneca PLC (NYSE:AZN) to report earnings on February, 1. They expect $0.44 earnings per share, down 63.64% or $0.77 from last year’s $1.21 per share. AZN’s profit will be $1.06 billion for 20.15 P/E if the $0.44 EPS becomes a reality. After $1.12 actual earnings per share reported by AstraZeneca PLC for the previous quarter, Wall Street now forecasts -60.71% negative EPS growth.

Cullen Capital Management Llc increased Sanofi (SNYNF) stake by 4,690 shares to 56,465 valued at $5.61M in 2017Q3. It also upped The Travelers Companies Inc. (NYSE:TRV) stake by 3,190 shares and now owns 556,970 shares. Welltower Inc. was raised too.

Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 16 have Buy rating, 0 Sell and 10 Hold. Therefore 62% are positive. AstraZeneca plc (ADR) had 41 analyst reports since July 31, 2015 according to SRatingsIntel. Credit Suisse downgraded the stock to “Underperform” rating in Tuesday, October 20 report. The stock has “Buy” rating by Deutsche Bank on Monday, September 14. The company was downgraded on Tuesday, March 15 by Jefferies. The stock of AstraZeneca PLC (NYSE:AZN) earned “Buy” rating by J.P. Morgan on Friday, December 29. As per Tuesday, January 19, the company rating was upgraded by Barclays Capital. The stock of AstraZeneca PLC (NYSE:AZN) has “Buy” rating given on Wednesday, October 18 by Citigroup. The stock has “Buy” rating by Piper Jaffray on Wednesday, August 9. The rating was upgraded by S&P Research to “Buy” on Friday, July 31. On Monday, February 8 the stock rating was downgraded by HBSC to “Hold”. The firm earned “Outperform” rating on Friday, September 22 by Bernstein.